Biofrontera Inc. Files Amendment No. 1 to Form S-1 Registration Statement

TL;DR

<b>Biofrontera Inc. has filed an amendment to its S-1 registration statement, indicating ongoing securities registration activities.</b>

AI Summary

Biofrontera Inc. (BFRIW) filed a Amended IPO Registration (S-1/A) with the SEC on March 20, 2024. Biofrontera Inc. filed an amendment (No. 1) to its Form S-1 Registration Statement on March 19, 2024. The filing relates to the registration of securities under the Securities Act of 1933. The company's principal executive offices are located at 120 Presidential Way, Suite 330, Woburn, MA 01801. The filing indicates Biofrontera Inc. is a non-accelerated filer, a smaller reporting company, and an emerging growth company. The registration statement number is 333-277811.

Why It Matters

For investors and stakeholders tracking Biofrontera Inc., this filing contains several important signals. This amendment suggests Biofrontera Inc. is actively managing its securities offerings and compliance with SEC regulations. The classification as a smaller reporting and emerging growth company may impact disclosure requirements and investor perception.

Risk Assessment

Risk Level: low — Biofrontera Inc. shows low risk based on this filing. The filing is an amendment to a registration statement, which is a standard procedural step and does not inherently indicate significant new risks or positive developments.

Analyst Insight

Monitor for further filings related to this registration statement to understand the specifics of the securities offering and its potential impact on the company's capital structure.

Key Numbers

• 333-277811 — SEC File Number (Registration number for the S-1 filing)
• 20240319 — Filing Date (Date the amendment was filed)
• 120 Presidential Way, Suite 330 — Principal Office Address (Woburn, MA 01801)
• 781-245-1325 — Business Phone (Contact number for principal executive offices)

Key Players & Entities

• Biofrontera Inc. (company) — Registrant name
• 333-277811 (registration_number) — SEC registration number
• 120 Presidential Way, Suite 330 Woburn, MA 01801 (address) — Registrant's principal executive offices
• Prof. Dr. Hermann Luebbert (person) — Chairman and Chief Executive Officer
• McGuireWoods LLP (company) — Legal counsel
• Stephen E. Older (person) — Legal counsel
• Andrew J. Terjesen (person) — Legal counsel
• Daniel Hakansson (person) — Corporate Counsel

FAQ

Industry Context

Biofrontera Inc. operates in the pharmaceutical preparations industry, focusing on medical devices and treatments.

Regulatory Implications

The filing is made under the Securities Act of 1933, which governs the registration of securities offered to the public.

What Investors Should Do

1. Review the full S-1/A filing for details on the securities being registered and the purpose of the offering.
2. Track future SEC filings from Biofrontera Inc. for updates on the registration effectiveness and any subsequent offerings.
3. Analyze the company's financial health and business strategy in conjunction with this securities registration activity.

Key Dates

• 2024-03-19: Amendment No. 1 to Form S-1 Filed — Indicates an update or addition to the initial registration statement.

Year-Over-Year Comparison

This is an amendment to a previous filing, indicating an update or continuation of a registration process rather than a new initial filing.

Key Financial Figures

• $0.001 — Convertible Preferred Stock, par value $0.001 per share (the &ldquo;Series B-1 Prefer
• $1.26 — price per share of our common stock was $1.26. The Selling Stockholders will offer
• $4 billion — market size is estimated to be roughly $4 billion for the three therapy types. Our primar
• $500 million — et, our targeted market is about 11% or $500 million of the total AK market (consisting of t
• $100 million — consisting of the current PDT market at $100 million and the portion of the market attribute
• $400 m — y treatments of more than 14 lesions at $400 million, assuming a tube price of $346).
• $346 — $400 million, assuming a tube price of $346). 6 Our second prescription drug lice

Filing Documents

• forms-1a.htm (S-1/A) — 586KB
• ex5-1.htm (EX-5.1) — 29KB
• ex23-1.htm (EX-23.1) — 4KB
• ex107.htm (EX-FILING FEES) — 27KB
• forms-1a_001.jpg (GRAPHIC) — 3KB
• ex5-1_001.jpg (GRAPHIC) — 4KB
• 0001493152-24-010552.txt (&nbsp;) — 657KB

RISK FACTORS

RISK FACTORS 8 SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS 13

USE OF PROCEEDS

USE OF PROCEEDS 14 DIVIDEND POLICY 15

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 16

DESCRIPTION OF SECURITIES AND CERTIFICATE OF INCORPORATION

DESCRIPTION OF SECURITIES AND CERTIFICATE OF INCORPORATION 17 PRIVATE PLACEMENT OF THE PREFERRED STOCK AND WARRANTS 23 SELLING STOCKHOLDERS 24 PLAN OF DISTRIBUTION 25 LEGAL MATTERS 26 EXPERTS 26 WHERE YOU CAN FIND MORE INFORMATION 26 INCORPORATION BY REFERENCE 26 i ABOUT THIS PROSPECTUS We and the Selling Stockholders have not authorized anyone to provide any information or to make any representations other than those contained in this prospectus. We and the Selling Stockholders take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. This prospectus is an offer to sell only the shares offered by this prospectus, but only under circumstances and in jurisdictions where it is lawful to do so. The information contained in this prospectus is current only as of its date. Our business, financial condition, results of operations and prospects may have changed since that date. For investors outside the United States: We and the Selling Stockholders have not done anything that would permit the sale of our common stock being offered by the Selling Stockholders in any jurisdiction where action for that purpose is required, other than in the United relating to, the offering of the shares and the distribution of this prospectus outside the United States . BASIS OF PRESENTATION As used in this prospectus, unless the context otherwise requires, references to &ldquo;we,&rdquo; &ldquo;us,&rdquo; &ldquo;our,&rdquo; the &ldquo;Company,&rdquo; &ldquo;Biofrontera&rdquo; and similar references refer to Biofrontera Inc. which includes its wholly owned subsidiary Bio-Fri GmbH. References in this prospectus to the &ldquo; Biofrontera Group &rdquo; (a related party) refer to Biofrontera AG and its consolidated subsidiaries, Biofrontera Pharma

Risk Factors

Risk Factors Investing in our common stock involves substantial risk. Our ability to execute our strategy is also subject to certain risks. The risks described under the heading &ldquo;Risk Factors&rdquo; included elsewhere in this prospectus and in our most recent Annual Report on Form 10-K , which is incorporated by reference herein, may cause us not to realize the full benefits of our strengths or may cause us to be unable to successfully execute all or part of our strategy. Some of the most significant challenges and risks include the following: Currently, our sole source of revenue is from sales of products we license from other companies. If we fail to comply with our obligations in the agreements under which we license rights from such third parties, or if the license agreements are terminated for other reasons, we could lose license rights that are important to our business. Certain important patents for our licensed product Ameluz &reg; expired in 2019. Although the process of developing generic topical dermatological products for the first time presents specific challenges that may deter potential generic competitors, generic versions of Ameluz &reg; may enter the market following the recent expiration of these patents. If this happens, we may need to reduce the price of Ameluz &reg; significantly and may lose significant market share. Our business depends substantially on the success of our principal licensed product Ameluz &reg; . If the Ameluz Licensor is unable to successfully obtain and maintain regulatory approvals or reimbursement for Ameluz &reg; for existing and additional indications, our business may be materially harmed. The Ameluz Licensor currently depends on a single unaffiliated contract manufacturer to manufacture Ameluz &reg; and has recently contracted with a second unaffiliated contract manufacturer to begin producing Ameluz &reg; . If the Ameluz Licensor fails to maintain its relationships with these manufacturers or if both

View Full Filing

View this S-1/A filing on SEC EDGAR